Acandis Gmbh Receives Approval For APERIO Hybrid Thrombectomy Device

Publisher: The Insight Partners

Acandis GmbH announced that it has received CE mark approval for its APERIO Hybrid Thrombectomy Device. The devices is intended to severe restoration of the arterial flow in ischemic stroke patients that are caused due to large intracranial vascular occlusion.

Acandis GmbH & Co. KG is among the medical devices company which is involved in the development of manufacture and marketing of neurovascular products. The products are used in the treatment of strokes, and the products are also used during the interventional neurologists for preventing strokes. The company is engaged in the research and development of the products and technologies that accomplish engineering stroke solutions.

The company’s production is done in Pforzheim and is distributed across the regions such as Europe, South America, Asia Pacific, and the Middle East. The company initiated its research and development in 2007 and started its production since 2009. Company’s first product was Acandis Open Cell Stent which is a self-expanding stent used in treating a neurovascular condition.

Neurothrombectomy devices are used to destroy blood clots in the cerebral neurovasculature. The neurothrombectomy devices utilize techniques such as mechanical, ultrasound, laser, or combination of techniques. The devices offer advantages such as faster recanalization in the bloodstream, enhanced efficiency during the treatment of large occlusions in the vessel and provides greater efficacy than lower down the risk of hemorrhagic events.